Literature DB >> 3373218

Differential alteration of various cholinergic markers in cortical and subcortical regions of human brain in Alzheimer's disease.

D M Araujo1, P A Lapchak, Y Robitaille, S Gauthier, R Quirion.   

Abstract

The main objective of the present study was to determine whether cholinergic markers (choline acetyltransferase activity and nicotinic and muscarinic receptors) are altered in Alzheimer's disease. Choline acetyltransferase activity in Alzheimer's brains was markedly reduced in various cortical areas, in the hippocampus, and in the nucleus basalis of Meynert. The maximal density of nicotinic sites, measured using the novel nicotinic radioligand N-[3H]methylcarbamylcholine, was decreased in cortical areas and hippocampus but not in subcortical regions. M1 muscarinic cholinergic receptor sites were assessed using [3H]pirenzepine as a selective ligand; [3H]pirenzepine binding parameters were not altered in most cortical and subcortical structures, although the density of sites was modestly increased in the hippocampus and striatum. Finally, M2-like muscarinic sites were studied using [3H]-acetylcholine, under muscarinic conditions. In contrast to M1 muscarinic sites, the maximal density of M2-like muscarinic sites was markedly reduced in all cortical areas and hippocampus but was not altered in subcortical structures. These findings reveal an apparently selective alteration in the densities of putative nicotinic and muscarinic M2, but not M1, receptor sites in cortical areas and in the hippocampus in Alzheimer's disease.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3373218     DOI: 10.1111/j.1471-4159.1988.tb02497.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  38 in total

Review 1.  Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.

Authors:  Paul A Lapchak
Journal:  Expert Rev Med Devices       Date:  2012-01       Impact factor: 3.166

Review 2.  α6β2* and α4β2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease.

Authors:  Maryka Quik; Susan Wonnacott
Journal:  Pharmacol Rev       Date:  2011-12       Impact factor: 25.468

3.  Cortical M1 receptor concentration increases without a concomitant change in function in Alzheimer's disease.

Authors:  Cassia R Overk; Christian C Felder; Yuan Tu; Doug A Schober; Kelly R Bales; Joanne Wuu; Elliott J Mufson
Journal:  J Chem Neuroanat       Date:  2010-03-27       Impact factor: 3.052

4.  Comparison of the effects of Alzheimer's disease, normal aging and scopolamine on human transient visual evoked potentials.

Authors:  A T Smith; F Early; G H Jones
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

5.  Amyloid beta-peptide disrupts carbachol-induced muscarinic cholinergic signal transduction in cortical neurons.

Authors:  J F Kelly; K Furukawa; S W Barger; M R Rengen; R J Mark; E M Blanc; G S Roth; M P Mattson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-06-25       Impact factor: 11.205

6.  Effect of a novel prolyl endopeptidase inhibitor, JTP-4819, on neuropeptide metabolism in the rat brain.

Authors:  K Toide; T Fujiwara; Y Iwamoto; M Shinoda; K Okamiya; T Kato
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-02       Impact factor: 3.000

7.  Nicotinic binding sites in cerebral cortex and hippocampus in Alzheimer's dementia.

Authors:  E D London; M J Ball; S B Waller
Journal:  Neurochem Res       Date:  1989-08       Impact factor: 3.996

8.  SR 46559A: a novel and potent muscarinic compound with no cholinergic syndrome.

Authors:  J P Kan; R Steinberg; F Oury-Donat; J C Michaud; O Thurneyssen; J P Terranova; C Gueudet; J Souilhac; R Brodin; R Boigegrain
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

9.  Effects of disrupting the cholinergic system on short-term spatial memory in rats.

Authors:  J S Andrews; J H Jansen; S Linders; A Princen
Journal:  Psychopharmacology (Berl)       Date:  1994-08       Impact factor: 4.530

Review 10.  Cholinergic markers in Alzheimer disease and the autoregulation of acetylcholine release.

Authors:  R Quirion
Journal:  J Psychiatry Neurosci       Date:  1993-11       Impact factor: 6.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.